Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr-Jun;41(2):106-113.
doi: 10.1016/j.htct.2018.09.006. Epub 2019 Feb 16.

Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon

Alan Rodrigues Andrade  1 , Daniel da Silva Leitão  2 , Igor Penha Paz  2 , Talitta Ribeiro Evangelista  2 , Vanessa Joia de Mello  2 , Moisés Hamoy  2
Affiliations

Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon

Alan Rodrigues Andrade et al. Hematol Transfus Cell Ther. 2019 Apr-Jun.

Abstract

Background: There has been a revolution in the treatment of Chronic Myeloid Leukemia since imatinib's introduction. However, patient adherence has a great impact on the response obtained with medical treatment. This study's objective was to analyze the drug adherence and the factors that influenced it in patients with Chronic Myeloid Leukemia in a referral hospital in the Brazilian Amazon.

Method: This was a retrospective study including 120 patients with Chronic Myeloid Leukemia from January 2002 to December 2014. The adherence was estimated by the Proportion of Days Covered and the persistence by Kaplan-Meier analysis. The data was analyzed in Epi Info 7® software and the relationship between the variables was analyzed by Fisher's exact test. A p-value lower than 0.05 was considered significant.

Results: Twenty-seven patients (22.5%) were considered non-adherent. There has been irregular medication use and disinterest in the treatment in 20.83% (n=25), of which 13 were considered non-adherent (p<0.001). A total of 26.67% (n=32) abandoned the treatment for a period. Of those, 56.25% (n=18) were non-adherent (p<0.001). Distance to the hospital, lack of medication and side-effects were all non-significant to low adherence. At the end of a 360-day follow-up, 44.16% (n=53) of patients presented a break in persistence, whose average was 255 days.

Conclusion: The adherence found in this study was similar to that found in others of its kind. The only factors that negatively influenced the adherence were disinterest and abandonment of treatment, which can reflect the need to individually educate Chronic Myeloid Leukemia patients.

Keywords: Adherence; Amazon; Chronic; Imatinib; Leukemia; Myelogenous.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustrative diagram of the process of composing the studied sample.
Figure 2
Figure 2
Boxplot of the proportion of days covered by groups.
Figure 3
Figure 3
Kaplan–Meier plot considering the break in persistence as the study phenomenon in follow-up.
Figure 4
Figure 4
Map of Brazil containing the demographic density of the sample.
Figure 5
Figure 5
Distribution of abandonment causes of TKI use.
See this image and copyright information in PMC

References

    1. Trivedi D., Landsman-Blumberg P., Darkow T., Smith D., McMorrow D., Mullins C.D. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Pharm [Internet] 2014;20(10):1006–1015. Available from: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18571 [accessed 15.02.17] - PMC - PubMed
    1. Kapoor J., Agrawal N., Ahmed R., Sharma S.K., Gupta A., Bhurani D. Factors influencing adherence to imatinib in indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis [Internet] 2015;7(1):e2015013. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344173/pdf/mjhid-7-1-e2015... [accessed 17.02.17] - PMC - PubMed
    1. Jabbour E.J., Kantarjian H., Eliasson L., Cornelison A.M., Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol [Internet] 2012;87:687–691. [accessed 05.03.17] - PMC - PubMed
    1. Santoleri F., Sorice P., Lasala R., Rizzo R.C., Costantini A. Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLOS ONE [Internet] 2013;8(2):e56813. Available from: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.00... [accessed 10.0.3.17] - PMC - PubMed
    1. Rego M.N., Metze K., Lorand-Metze I. Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. Clinics [Internet] 2015;70(5):322–325. Available from: http://www.scielo.br/pdf/clin/v70n5/1807-5932-clin-70-05-322.pdf [accessed 22.0.3.17] - PMC - PubMed